Skip to main content
dana-farber.org

Advances in Cancer Medicine: Our Momentum of Discovery

 

Featured Content |Content Library

Acute Myeloid Leukemia Triplet Therapies: Easy as 1, 2, 3 News

Acute Myeloid Leukemia Triplet Therapies: Easy as 1, 2, 3

Clinical Trials Unite Doctors, Researchers, and Patients to Advance Treatments News

Clinical Trials Unite Doctors, Researchers, and Patients to Advance Treatments

CME: ASH 2025 Highlights Course

CME: ASH 2025 Highlights

Forcing Cancer to Grow Up: Dana-Farber Scientists Reprogram Tumors to Behave Normally News

Forcing Cancer to Grow Up: Dana-Farber Scientists Reprogram Tumors to Behave Normally

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants News

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer News

Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer

Education/CME

Receive Dana-Farber's
e-newsletter, Momentum,
to learn of advances in cancer research and care, current clinical trials, and upcoming CME programs.